scholarly journals IMMUNOHISTOCHEMICAL APPROACH TO DIFFERENTIAL DIAGNOSIS OF NON-SMALL CELL LUNG CARCINOMA IN BRONCHOSCOPIC BIOPSY SPECIMENS

2016 ◽  
Vol 55 (2) ◽  
pp. 31-34
Author(s):  
Žaklina Mijović ◽  
◽  
Nikola Živković ◽  
Ana Stefanović ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 822-826
Author(s):  
Wei Zhang ◽  
Qingyu Cai ◽  
Guoli Wei

The differential diagnosis of advanced lung cancer is difficult in clinical practice. Our study aims to compare the value of diffusion weighted imaging (DWI) with short-term inversion recovery sequence (STIR) for sagittal imaging in the differential diagnosis of lung cancer. 149 patients with non-small cell lung carcinoma (NSCLC) were enrolled and underwent DWI and STIR sagittal imaging. To quantify cancer types, we evaluated the apparent diffusion coefficient (ADC) value on DWI and the contrast ratio (CRs) on sagittal imaging. The ADC values of subclasses in NSCLC were significantly higher than small cell lung carcinoma (SCLC) (p <0.01). The mean CRs were 1.59 for SCLC and 1.30 for NSCLC with a significant difference (p < 0.01). Large cell carcinomas (LCC) and adenocarcinomas have significant differences compared to small cell carcinomas (SCC) without difference between squamous cell carcinomas (p > 0.05); this is also the case for CRs. Squamous cell carcinoma and adenocarcinoma have significant differences compared to SCC without difference in LCC (p > 0.05). Qualitative evaluation of the feasible thresholds DWI and STIR showed that the thresholds were 0.9810−3 mm2/s and 1.37 respectively. The specificity and accuracy was 78.5% is 85.3% for DWI, which was significantly higher than STIR (56.3% and 61.0%). The combination of DWI and STIR sequences was superior to DWI alone with an accuracy rate of 94.3%. DWI is more helpful than STIR in differentiating SCLC and NSCLC, and their combined use can significantly improve diagnosis accuracy.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 11069-11069
Author(s):  
D. Lebanony ◽  
H. Benjamin ◽  
S. Gilad ◽  
K. Ashkenazi ◽  
D. Nonaka ◽  
...  

11069 Background: Recent advances in biologically directed therapies for non-small cell lung carcinoma (NSCLC) emphasize the need for more accurate sub-classification of NSCLC, as treatment may be dictated by histologic subtype. In particular, squamous histology can be a counter-indication for treatment by VEGF inhibitors. MicroRNAs are highly tissue-specific biomarkers with potential clinical applicability for defining cancer type and origin. MicroRNAs are well preserved in formalin fixed tissue, making them ideal candidates for molecular markers for use in routinely processed material. Here we report on the development and performance of a microRNA-based assay for the differential diagnosis of squamous from non-squamous NSCLC. Methods: We developed protocols for extraction of high-quality RNA that retain the microRNA fraction from FFPE archival tissue samples. MicroRNA microarrays were used to profile more than a hundred NSCLC samples. Specific microRNA qRT-PCR was used to validate results, and to develop a diagnostic assay. Results: We identified a microRNA biomarker that is strongly overexpressed in squamous cell NSCLC. A diagnostic assay (miRview squamous) was developed, that utilizes qRT-PCR measurement of this microRNA, normalized by an additional microRNA and a small nuclear RNA. This assay was validated on a blinded test set of 64 tumor samples, and had sensitivity of 97% and specificity of 91%. More than ¾ of the samples were classified with high confidence, and these classifications were accurate in 96% of the cases. Conclusions: MicroRNAs are becoming an important tool for classification of cancers. A diagnostic assay based on the specificity of a single microRNA accurately identifies squamous from non-squamous NSCLC. This assay provides an important new tool for the classification of NSCLC. [Table: see text]


2020 ◽  
Vol 16 (1) ◽  
pp. 127
Author(s):  
Ved Prakash ◽  
SatyendraKumar Singh ◽  
Anjana Singh ◽  
Ravi Kant ◽  
TajindraSingh Saluja ◽  
...  

Haigan ◽  
2021 ◽  
Vol 61 (3) ◽  
pp. 189-194
Author(s):  
Tatsuya Miyamoto ◽  
Takeshi Mimura ◽  
Atsushi Kagimoto ◽  
Chika Nakashima ◽  
Junichi Zaitsu ◽  
...  

2004 ◽  
Vol 48 (5) ◽  
pp. 608-612 ◽  
Author(s):  
Johanna M. M. Grefte ◽  
Maria R. J. Salet-van de Pol ◽  
Johanna H. Gemmink ◽  
Johan Bulten ◽  
Antonius G. J. M. Hanselaar ◽  
...  

2016 ◽  
Vol 8 (1) ◽  
pp. 16-19 ◽  
Author(s):  
Dogu Aydin ◽  
Finn Somnier ◽  
Lisbeth H. Lassen

Introduction: The occurrence of more or less monosymptomatic paraneoplastic choreoathetosis associated with anti-CRMP5/CV2 antibodies is rare. Typically, such autoantibodies are associated with a more classical syndrome - paraneoplastic encephalomyelitis. Frequently, small cell lung carcinoma (SCLC) is the related neoplastic finding. Case Report: We present a 71-year-old woman who developed visual symptoms with papilledema and chorea. Anti-CRMP5/CV2 antibodies were a feature of both the serum and cerebrospinal fluid. Although SCLC was suspected already at the time of the initial examinations, no signs of primary or metastatic tumors were revealed on chest X-ray, MRI or whole-body PET scan. EEG and bronchoscopy were also unremarkable. However, 6 months after the onset, a repeated PET scan and subsequent bronchoscopic biopsy revealed SCLC. In spite of chemotherapy, the SCLC progressed, and the patient died 14 months after the onset of the symptoms. Conclusion: We report paraneoplastic choreoathetosis associated with anti-CRMP5/CV2 antibodies. Such published case histories are rare. Although expected, we did not find any reduced signal intensity at the basal ganglia on the T1-weighted or increased intensity on the T2-weighted MRI scans.


Sign in / Sign up

Export Citation Format

Share Document